within Pharmacolibrary.Drugs.ATC.D;

model D07AD01
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00025,
    adminDuration  = 600,
    adminMass      = 0.05 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D07AD01</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Clobetasol is a super-high potency synthetic corticosteroid used topically for the treatment of severe dermatoses such as psoriasis, eczema, and lichen planus. It is available as creams, ointments, and solutions and is approved for use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are based on estimated and indirect data due to the lack of published human PK studies. Clobetasol is typically applied topically, and systemic absorption in healthy adults is minimal except under occlusion or on damaged skin.</p><h4>References</h4><ol><li><p>Varoni, EM, et al., &amp; Lodi, G (2012). Pharmacokinetics study about topical clobetasol on oral mucosa. <i>Journal of oral pathology &amp; medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology</i> 41(3) 255–260. DOI:<a href=\"https://doi.org/10.1111/j.1600-0714.2011.01087.x\">10.1111/j.1600-0714.2011.01087.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21950548/\">https://pubmed.ncbi.nlm.nih.gov/21950548</a></p></li><li><p>Ghirardo, S, et al., &amp; Tornese, G (2021). Topical Clobetasol: An Overlooked Cause of Cushing Syndrome. <i>Endocrine, metabolic &amp; immune disorders drug targets</i> 21(12) 2300–2302. DOI:<a href=\"https://doi.org/10.2174/1871530321666210426131423\">10.2174/1871530321666210426131423</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33902425/\">https://pubmed.ncbi.nlm.nih.gov/33902425</a></p></li><li><p>Feldman, SR, &amp; Yentzer, BA (2009). Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulations. <i>American journal of clinical dermatology</i> 10(6) 397–406. DOI:<a href=\"https://doi.org/10.2165/11311020-000000000-00000\">10.2165/11311020-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19824740/\">https://pubmed.ncbi.nlm.nih.gov/19824740</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D07AD01;
